Falk G. Bechara

机构：University Hospitals of the Ruhr-University of Bochum, St. Josef-Hospital, Austrian Society of Dermatology and Venereology, Hidradenitis Suppurativa Foundation, Ruhr University Bochum · ORCID：0000-0003-0418-521X

发表论文 380 篇 · 总被引 10015 次 · h-index 52

代表论文

• Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics (2025 · Journal of the European Academy of Dermatology and Venereology · 被引 7)
• Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension (2025 · Journal of the American Academy of Dermatology · 被引 6)
• Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt Treatment (2026 · American Journal of Clinical Dermatology · 被引 4)
• Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa (2026 · Journal of the European Academy of Dermatology and Venereology · 被引 3)
• 62279 Remibrutinib in patients with moderate to severe hidradenitis suppurativa: Patient reported outcomes from a randomized, phase 2, double-blind, placebo-controlled platform study (2025 · Journal of the American Academy of Dermatology · 被引 3)
• Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure (2026 · JAMA Dermatology · 被引 2)